Dr. Kumardeep Dutta Chaudhary


MBBS, MD (Internal Medicine), DNB (Medical Oncology)

Consultant Medical Oncology

Rajiv Gandhi Cancer Institute, Sector-5, Rohini, Delhi-110085

SPECIALIZED AREAS

Treating BRCA1 and BRCA2 positive Breast and Ovarian cancer patients.
Treating those who are suffering from dual or more malignancy simultaneously like Breast and Ovarian cancer, Breast and blood cancer.
Chemoimunotherapy in Lung cancer, Head and Neck cancer, Breast cancer, Colorectal cancer.

EDUCATIONAL BACKGROUND

DNB (Medical Oncology), National Board of Examination, New Delhi, India,2010
MD (Internal Medicine), Silchar Medical College, Assam, 2004.
MBBS, Silchar Medical College, Silchar, Assam, 1996

EXPERIENCES

Thesis Guide for DNB students of Rajiv Gandhi Cancer Institute, Delhi since 2014.
2010 to present - Fellows (Medical Oncology), Rajiv Gandhi Cancer Institute and Research Centre, Delhi
2008- 2010 - Senior Resident (Medical Oncology), Rajiv Gandhi Cancer Institute and Research Centre, Delhi
2000- 2003 - Junior Resident, Internal Medicine, Silchar Medical College, Assam

MEMBERSHIPS

Life member Association of physician of India (API)
International Association for the study of Lung Cancer. (IASLC)
Member, American Society of Clinical Oncology (ASCO)

ABOUT

Dr Kumardeep Dutta Choudhury is an experienced medical oncologist with more than 10 years of experience. He is treating patients of Breast, lung, colon and rectum cancers, sarcoma, lymphoma and myeloma and those who are suffering from familial cancer syndromes. Beside this he is administering chemotherapy via central line (PORT, PICC and Neck lines) and regional chemotherapy like intraperitoneal, intrathecal chemotherapy, target therapy and immunotherapy.

PROFESSIONAL JOURNEY

ACHIEVEMENTS
Treated maximum number of patients of Triple negative Breast Cancer and Her 2 neu positive Breast cancer which are considered aggressive disease, in a private setup in North India.
Treated maximum number of patients of Ovarian Cancer with intraperitoneal chemotherapy in a private setup in India.
Largest series of patients treated with mTor inhibitor.
Routinely testing patients for familial cancer syndromes and treating accordingly.
Routinely doing genomic profile of cancer types and managing patients accordingly.
AWARDS
Samita Mishra Memorial Foundation for Cancer Research Excellence Award for Active Role and Leadership in Cancer Bhagao Campaign. 2014
PUBLICATIONS
D.C. Kumardeep, Sharma P.C, P.R.N. Borbhuiya, Medical Complications of obesity, presented at APICON (Assam Chapter) 2002.
D.C. Kumardeep, Sharma P.C, Prevelance of Dyslipidemia in healthy general population of Silchar town, presented at APICON (Assam Chapter) 2002.
D.C. Kumardeep, Sharma P.C, Management of Dyslipidemia, published as update article in APICON (Assam Chapter) 2002.
D.C. Kumardeep, Gupta D, Agarwal A, Bhurani D, Response to Imatinib in Chronic Myeloid Leukemia by Cytogenetics, presented at Golden Jubilee Conference of Indian Society of Hematology & Transfusion Medicine Organized by Deptt. Of Hematology, AIIMS, New Delhi, 2009.
Choudhury KD, Doval DC, Azam S, Mehta A, Pruthi A, Batra U, Kumar K., A report of sarcomatoid carcinoma of the gall bladder treated with palliative docetaxel and gemcitabine chemotherapy. J Gastroinstestinal cancer, 2014 Dec;45 Suppl 1;270-4,doi: 10.1007/s 12029-014-9654-3.PMID: 25326734
Dutta K, Doval DC, Batra U,Talwar V. Neoadjuvant chemotherapy in breast cancer: review of literature.J Indian Medical Association 2013 Sep;111(9):629-31. Review.PMID: 24968534
Choudhury KD, Doval DC, Azam S, Batra U, Talwar V,Gupta SK,Mehta A.Epidermal growth factor receptor muatio in lung adenocarcinoma in India: A single center study. J Carcinog. 2013 Jul 12;12;12.doi:10.4103/1477-3163.114970.e Collection 2013PMID:23961259
K. Dutta, A. Upadhyay, V. Goel, U. Batra, P. Goyal, M. Aggarwal, D. C. Doval Two cases of ovarian carcinoma with endobronchial metastases: Rare presentation. South Asian Journal of Cancer. Vol 4, Issue 3, July – Sept 2015.
DC Kumardeep, DC Doval, Singha R et al. Profile of Anaplastic Lymphoma Kinase Fusion Oncogene Positive Patients with Non Small Cell Lung Cancer. J of Carcinogenesis Vol15, April 2016.
DC Kumardeep, Sharma A, Doval DC et al: Efficacy and safety profile of eribulin mesylate in advanced breast cancer. Single centre experience from India. Accepted for Poster presentation (display) at ESMO Asia 2016 Congress. 16-19 December 2016
Register Now